Literature DB >> 10799910

Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis.

C W Frevert1, G Matute-Bello, S J Skerrett, R B Goodman, O Kajikawa, C Sittipunt, T R Martin.   

Abstract

CD14, a pattern recognition receptor found on myeloid cells, is a critical component of the innate immune system that mediates local and systemic host responses to Gram-negative and Gram-positive bacterial products. Previous studies in normal animals have tested the effect of CD14 blockade on the systemic response to i.v. LPS. The goals of the study were to determine whether CD14 blockade protected against the deleterious systemic response associated with Escherichia coli pneumonia and to determine whether this strategy affected the pulmonary response to tissue infection. Rabbits were pretreated with either anti-CD14 mAb or isotype control mAb at 2.5 mg/kg. E. coli (1 x 109 CFU) was inoculated into the lungs, and the animals were observed for either 4 or 24 h. The blockade of CD14 improved the mean arterial blood pressure (p = 0.001) and decreased the i.v. fluid requirements (p = 0.01). Although this therapy protected the vascular compartment, rabbits treated with anti-CD14 mAb had increased bacterial burdens in the bronchoalveolar lavage fluid recovered from the instilled lung (p = 0.005) and widened alveolar-arterial oxygen difference. Blockade of CD14 prevents the deleterious systemic responses that occur in sepsis; however, other measures are necessary to control bacterial proliferation at the primary site of infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799910     DOI: 10.4049/jimmunol.164.10.5439

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  [Endotoxins. Pathogenetic meaning of sepsis].

Authors:  H Rensing
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  ß-adrenergic stimulation increases macrophage CD14 expression and E. coli phagocytosis through PKA signaling mechanisms.

Authors:  Kuzhali Muthu; Li-K He; Andrea Szilagyi; Patrick Strotmon; Richard L Gamelli; Ravi Shankar
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

Review 3.  Innate immunity in the lungs.

Authors:  Thomas R Martin; Charles W Frevert
Journal:  Proc Am Thorac Soc       Date:  2005

Review 4.  Acute lower respiratory tract infection.

Authors:  Joseph P Mizgerd
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

5.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

6.  Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans.

Authors:  C Retini; T R Kozel; D Pietrella; C Monari; F Bistoni; A Vecchiarelli
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  CD47 deficiency protects mice from lipopolysaccharide-induced acute lung injury and Escherichia coli pneumonia.

Authors:  Xiao Su; Mette Johansen; Mark R Looney; Eric J Brown; Michael A Matthay
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.

Authors:  Thierry Roger; Céline Froidevaux; Didier Le Roy; Marlies Knaup Reymond; Anne-Laure Chanson; Davide Mauri; Kim Burns; Beat Michel Riederer; Shizuo Akira; Thierry Calandra
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-30       Impact factor: 11.205

Review 9.  Role of CD14 in lung inflammation and infection.

Authors:  Adam Anas; Tom van der Poll; Alex F de Vos
Journal:  Crit Care       Date:  2010-03-09       Impact factor: 9.097

Review 10.  Advances in sepsis therapy.

Authors:  Thomas Glück; Steven M Opal
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.